The Latest

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Following a $1.5 billion licensing deal with stealthy startup Sentivera, Haisco Pharmaceutical now ranks among the sector's most prolific China-based partners since the start of 2025, BioPharma Dive data show.

    Updated 17 hours ago
  • An illustration of beta amyloid plaques and tau in the brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip

    Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test

    Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.

  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Obesity drugs

    Roche commits to lean-mass preservation with Hanmi obesity deal

    For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.

  • Illustration of GLP-1 weight loss drugs with an injection pen, vial, syringe and cost and weight-management icons.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    How cost and perception could reshape the GLP-1 market

    As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

  • A picture of a Moderna building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    Cancer vaccine win restores Wall Street’s faith in Moderna

    Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet. 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA extends review of Capricor cell therapy; Pain drug startup to go public

    The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    So far in 2026, RA Capital and OrbiMed again rank as the most active investors tracked by BioPharma Dive. But multiple corporate venture arms are in the top 10 this year as well.

    Updated Aug. 13, 2026
  • Imaging scans of a human spine are illuminated from behind for review.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Regeneron to challenge Ipsen as FDA clears bone disease drug

    Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.

    FDA
  • A sign reading Ultragenyx hangs on the side of a glass office building.
    Image attribution tooltip
    Sundry Photography via Getty Images
    Image attribution tooltip

    Ultragenyx, after setbacks, nabs first gene therapy approval

    The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Shareholder pressures Capricor; Lilly dives deeper into vaccines

    Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.

  • An illustration of immune cells attacking a tumor.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma

    At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.

  • FDA
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip
    Trump administration

    Trump nominates policy aide Overton to lead FDA

    Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White House Domestic Policy Council.

    Updated Aug. 19, 2026
    FDA
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx’s bet on a GLP-1 blocker pays off

    A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    BioMarin’s planned purchase of Alesta Therapeutics brings the tally of bigger-ticket acquisitions of rare disease drugmakers to half a dozen this year.

    Updated Aug. 10, 2026
  • Illustration of a lipid nanoparticle carrying messenger RNA into a human cell, the biotech behind Moderna's game-changing flu vax
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax

    Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.

  • Imaging scans of a human spine are illuminated from behind for review.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin acquires experimental drug for rare bone disorder in $275M deal

    The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.

  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer

    An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.

  • As pharma manufacturing investment skyrockets, investments have poured into regional biotech hubs eager from NY to Kansas City
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biotech initiatives pick up as more regions race to become hubs

    New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.

  • Pills lie on top of hundred dollar bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Leo Pharma buys rare skin disease drug in $435M deal

    Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Drug startups have banked $6 billion in IPOs so far in 2026, more than the combined amount raised by this point in the previous four years.

    Updated Aug. 7, 2026
  • Formation Bio has tapped Biogen and Pfizer vet Mike Ehlers to be its new R&D chief
    Image attribution tooltip
    Permission granted by Image courtesy of Formation Bio
    Image attribution tooltip
    Profile

    Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’

    Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    AstraZeneca scores in lung cancer; Sandoz inks a China deal

    A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    EyePoint plummets on pivotal data for main drug

    Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.

  • A financial graph on an abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Argenx jumps on Phase 3 data for blockbuster Vyvgart

    The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments. 

  • Left to right: Gregory Oakes, chief executive officer of Slate Medicines, and Neil Buckley, chief operating officer of Slate Medicines.
    Image attribution tooltip
    Permission granted by Slate Medicines
    Image attribution tooltip

    Slate, Fulcrum to combine in reverse merger

    Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.